Anti-KRT19 Antibody (6B199) is a Mouse antibody targeting KRT19. Anti-KRT19 Antibody (6B199) can be used in WB,FCM,IP.

Mouse IgG3

6B199

Human

1. KRT19 was immunoprecipitated using:
-Lane A:0.5 mg HepG2 Whole Cell Lysate.
-4 µL anti-KRT19 mouse monoclonal antibody and 15 μl of 50 % Protein G agarose.
-Primary antibody:
-Anti-KRT19 mouse monoclonal antibody, at 1:100 dilution.
-Secondary antibody:
-Dylight 800-labeled antibody to Mouse IgG (H+L), at 1:7500 dilution.
-Developed using the odyssey technique.
-Performed under reducing conditions.
-Predicted band size: 44 kDa.
-Observed band size: 40 kDa.
2. Anti-KRT19 mouse monoclonal antibody at 1:500 dilution.
-Lane A: HepG2 Whole Cell Lysate.
-Lane B: HCT116 Whole Cell Lysate.
-Lane C: A431 Whole Cell lysate.
-Lysates/proteins at 30 μg per lane.
-Secondary
-Goat Anti-Mouse IgG H&L (Dylight800) at 1/15000 dilution.
-Developed using the Odyssey technique.
-Performed under reducing conditions.
-Predicted band size:44 kDa.
-Observed band size:42 kDa.
3. Flow cytometric analysis of Human KRT19 expression on A431 cells. The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), stained with purified anti-Human KRT19, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
4. Anti-KRT19 mouse monoclonal antibody at 1:500 dilution.
-Lane A: HepG2 Whole Cell Lysate.
-Lane B: KRT19 konckout HepG2 Whole Cell lysate.
-Lysates/proteins at 30 μg per lane.
-Secondary
-Goat Anti-Mouse IgG (H+L)/HRP at 1/10000 dilution.
-Developed using the ECL technique.
-Performed under reducing conditions.
-Predicted band size:44 kDa

WB: 1:500-1:2000; FCM: 1:25-1:100; IP: 0.5-2 μL/mg of lysate

Monoclonal

Unconjugated

A synthetic peptide: N-terminus of the human KRT19

Human